Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of Therapeutic Inducers of Natural Killer Killing (ThINKK) Adoptive Immunotherapy: Feasibility, Safety and Pharmacodynamics in Children Undergoing Allogenic Hematopoietic Transplantation for Leukemia or Neuroblastoma

NCT07518654 is registered in ClinicalTrials.gov with Michel Duval as lead sponsor.

NCT NCT07518654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07518654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of Therapeutic Inducers of Natural Killer Killing (ThINKK) Adoptive Immunotherapy: Feasibility, Safety and Pharmacodynamics in Children Undergoing Allogenic Hematopoietic Transplantation for Leukemia or Neuroblastoma
Lead sponsor
Michel Duval
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
May 1, 2029
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoetic stem cell transplant, hematopoetic stem cell transplantation, leukaemia (acute lymphoblastic), leukaemia (acute myeloid), leukaemia, lymphoblastic, acute, leukemia (both all and aml), leukemia acute myeloid, leukemia acute myeloid - aml, neuroblastoma, neuroblastoma, metastatic